Blueshot Blog
Expert guides on GLP-1 medications, weight management, and healthy living
NewsGLP-1 Drugs Just Became the World's Best-Selling Drug Class (2026)
Novo Nordisk and Eli Lilly's GLP-1 revenue hit $60B+ annualized in Q1 2026, overtaking oncology. What record sales mean for pricing, supply, and access.
Medication GuideGLP-1 and Pancreatitis: Separating Real Risk from Internet Panic (2026)
Pancreatitis is on every GLP-1 label. Clinical trial rates are under 0.5%. Here's what STEP, SURMOUNT, and SELECT actually show.
Medication GuideGLP-1 and Thyroid Cancer: What the Black Box Warning Actually Means (2026)
Every GLP-1 drug carries a boxed warning about thyroid cancer. But 145,000-patient cohort data and 15 years of surveillance say the human risk is near zero. Here's the evidence.
Medication GuideGLP-1 and Gallbladder Problems: What the Data Actually Shows (2026)
Gallstones and cholecystitis are a real risk on semaglutide and tirzepatide — about 2–3% in trials vs 1% on placebo. Here's why it happens, who's most at risk, and what to watch for.
Medication GuideYour Stomach on a GLP-1: Gastroparesis, Nausea, and What the Evidence Actually Says
Gastroparesis fears, sulfur burps, nausea that makes you question everything — here's what the clinical data says about GLP-1s and your gut, and when to worry.
Medication GuideGLP-1 Long-Term Safety: What the Trial Data Shows (2026)
LEADER, REWIND, SELECT, SOUL, FLOW — 50,000+ patients, up to 5.4 years. What the long-term data says about thyroid, heart, kidneys, gallbladder, and more.
Medication GuideEvery Pill You Take With a GLP-1 — What Actually Interacts and What Doesn't
You're on Wegovy or Mounjaro and you take other meds too. Here's what the prescribing labels, clinical data, and your pharmacist actually worry about.
Medication GuideGLP-1 Weight Loss Plateau: Why You Stalled and What Actually Works
Most people hit a wall at months 3-6 on semaglutide or tirzepatide. The plateau isn't failure — it's biology. Here's what the STEP and SURMOUNT data says about breaking through.
Medication GuideYour Kidneys on GLP-1: What the FLOW Trial Found (and What It Means for You)
The FLOW trial stopped early because semaglutide cut major kidney events by 24%. If you have type 2 diabetes and CKD, here's what the 2024 data means for your kidneys.
NewsOral Semaglutide Hits 400K Users — Where the GLP-1 Pill Stands Globally
Four months after US launch, oral semaglutide for obesity has 400,000 patients on it. Here's which markets have it, which are next, and what the real-world data says so far.
NewsYour Liver Might Already Be Getting Better — GLP-1 and Fatty Liver Disease
If you're on a GLP-1 for weight loss, the ESSENCE and SYNERGY-NASH trials suggest your liver may be healing too. Here's what the 2024-2025 data actually shows.
NewsGLP-1 Failed the Alzheimer's Trial — But the Brain Story Isn't Over
Semaglutide failed the EVOKE+ Alzheimer's trial. Yet observational data still shows 40-70% lower dementia risk. Prevention and treatment are different questions.
Medication GuideYour Mood on GLP-1: What the Evidence Says About Depression, Anxiety, and 'Food Noise'
GLP-1 drugs changed how millions eat. Do they also change how you feel? Here's what clinical trials, brain science, and 2 million patient records actually show.
Medication GuideGLP-1 Drugs and Cancer Risk: What the 2026 Evidence Actually Shows
A 281,656-person study found GLP-1 users had 36% lower colorectal cancer risk than aspirin users. JAMA Oncology data adds 17% lower overall cancer risk across 14 types. Here's what the evidence means for you.
Medication GuideGLP-1 cost in 2026: insurance, cash price, and every path to coverage
Wegovy lists at $1,349. Zepbound at $1,059. Medicare covers both in July for $50. Every payment path — insurance, cash, coupons, and PA denial appeals.
Medication GuideGLP-1 Hair Loss in 2026: Why Month 4 Is the Shower-Drain Moment, and What Actually Helps
STEP 1 said 3.0%. SURMOUNT-1 said 5.7%. The mechanism is telogen effluvium, the timing is month 3 to 5, and the fix is not biotin gummies.
Medication GuideGLP-1 and Pregnancy in 2026: Washout Windows, the Pill Trap, and What OB-GYNs Now Say
Washout windows by molecule, the oral-contraceptive failure your prescriber probably didn't mention, and what regulators say in 2026.
Medication GuideGLP-1 and surgery: when to pause Wegovy, Zepbound, and Ozempic
When to hold Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, and Foundayo before anesthesia — exact pause windows, brand-by-market, and what to ask your team.